Literature DB >> 21220479

KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy.

Ashkan Mortezavi1, Thomas Hermanns, Hans-Helge Seifert, Martin K Baumgartner, Maurizio Provenzano, Tullio Sulser, Maximilian Burger, Matteo Montani, Kristian Ikenberg, Ferdinand Hofstädter, Arndt Hartmann, Rolf Jaggi, Holger Moch, Glen Kristiansen, Peter J Wild.   

Abstract

PURPOSE: To analyze rates of expression of karyopherin alpha 2 (KPNA2) in different prostate tissues and to evaluate the prognostic properties for patients with primary prostate cancer. EXPERIMENTAL
DESIGN: Tissue microarrays (TMA) contained 798 formalin-fixed, paraffin-embedded prostate tissue cores from two different institutes of pathology. TMAs were stained immunohistochemically for KPNA2 and NBS1. SiRNA technologies were used to inhibit KPNA2 expression in vitro, and the effect of this inhibition on cellular viability was determined. Efficiency of knockdown experiments was determined by Western blot analysis.
RESULTS: KPNA2 expression was significantly upregulated in carcinomas of the prostate, especially in metastatic and castration-resistant prostate cancer samples. Positive nuclear KPNA2 immunoreactivity was identified as a novel predictor of biochemical recurrence after radical prostatectomy (n = 348), and was independent of the well-established predictive factors preoperative PSA value, Gleason score, tumor stage, and surgical margin status. These results were validated by analyzing a second and independent prostate cancer cohort (n = 330). Further, in vitro experiments showed that the cell proliferation and viability of PC3 cells was significantly reduced when KPNA2 expression was inhibited. KPNA2 knockdown did not induce PARP cleavage as marker for apoptosis. No significantly increased sub-G(1) fraction could be found by FACS analysis.
CONCLUSIONS: KPNA2 is a novel independent prognostic marker for disease progression after radical prostatectomy. This allows to identify patients who need more aggressive treatment. It can moreover be speculated that patients not suited for surveillance regimens might be identified at initial biopsy by a positive KPNA2 immunohistochemistry. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220479     DOI: 10.1158/1078-0432.CCR-10-0081

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

1.  Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas.

Authors:  K Gousias; A J Becker; M Simon; P Niehusmann
Journal:  J Neurooncol       Date:  2012-07-07       Impact factor: 4.130

2.  SPOP mutations in prostate cancer across demographically diverse patient cohorts.

Authors:  Mirjam Blattner; Daniel J Lee; Catherine O'Reilly; Kyung Park; Theresa Y MacDonald; Francesca Khani; Kevin R Turner; Ya-Lin Chiu; Peter J Wild; Igor Dolgalev; Adriana Heguy; Andrea Sboner; Sinan Ramazangolu; Haley Hieronymus; Charles Sawyers; Ashutosh K Tewari; Holger Moch; Ghil Suk Yoon; Yong Chul Known; Ove Andrén; Katja Fall; Francecsa Demichelis; Juan Miguel Mosquera; Brian D Robinson; Christopher E Barbieri; Mark A Rubin
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

3.  TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.

Authors:  Anna C Groner; Laura Cato; Jonas de Tribolet-Hardy; Tiziano Bernasocchi; Hana Janouskova; Diana Melchers; René Houtman; Andrew C B Cato; Patrick Tschopp; Lei Gu; Andrea Corsinotti; Qing Zhong; Christian Fankhauser; Christine Fritz; Cédric Poyet; Ulrich Wagner; Tiannan Guo; Ruedi Aebersold; Levi A Garraway; Peter J Wild; Jean-Philippe Theurillat; Myles Brown
Journal:  Cancer Cell       Date:  2016-05-26       Impact factor: 31.743

4.  Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.

Authors:  Jean-Philippe P Theurillat; Namrata D Udeshi; Wesley J Errington; Tanya Svinkina; Sylvan C Baca; Marius Pop; Peter J Wild; Mirjam Blattner; Anna C Groner; Mark A Rubin; Holger Moch; Gilbert G Prive; Steven A Carr; Levi A Garraway
Journal:  Science       Date:  2014-10-02       Impact factor: 47.728

5.  Quantitative proteomics reveals regulation of karyopherin subunit alpha-2 (KPNA2) and its potential novel cargo proteins in nonsmall cell lung cancer.

Authors:  Chun-I Wang; Kun-Yi Chien; Chih-Liang Wang; Hao-Ping Liu; Chia-Chen Cheng; Yu-Sun Chang; Jau-Song Yu; Chia-Jung Yu
Journal:  Mol Cell Proteomics       Date:  2012-07-25       Impact factor: 5.911

6.  Inhibition of KPNA4 attenuates prostate cancer metastasis.

Authors:  J Yang; C Lu; J Wei; Y Guo; W Liu; L Luo; G Fisch; X Li
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

7.  Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.

Authors:  Punit Saraon; Daniela Cretu; Natasha Musrap; George S Karagiannis; Ihor Batruch; Andrei P Drabovich; Theodorus van der Kwast; Atsushi Mizokami; Colm Morrissey; Keith Jarvi; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2013-02-26       Impact factor: 5.911

8.  The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence.

Authors:  Chuanbo Zhang; Bhaskar V Kallakury; Jeffrey S Ross; Rajshree R Mewani; Christine E Sheehan; Isamu Sakabe; George Luta; Deepak Kumar; Sivaramakrishna Yadavalli; Joshua Starr; Taduru L Sreenath; Shiv Srivastava; Harvey B Pollard; Ofer Eidelman; Meera Srivastava; Usha N Kasid
Journal:  Int J Cancer       Date:  2013-01-10       Impact factor: 7.396

9.  Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor.

Authors:  Li Ni; Ryan Llewellyn; Cristina T Kesler; Joshua B Kelley; Adam Spencer; Chelsi J Snow; Leonard Shank; Bryce M Paschal
Journal:  Mol Cell Biol       Date:  2013-10-07       Impact factor: 4.272

10.  Karyopherin a2 and chromosome region maintenance protein 1 expression in meningiomas: novel biomarkers for recurrence and malignant progression.

Authors:  Konstantinos Gousias; Pitt Niehusmann; Gerrit H Gielen; Matthias Simon
Journal:  J Neurooncol       Date:  2014-03-25       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.